The anti-dementia drugs: Myth, hype or reality?

Current Opinion in Neurology

Volumn 16, Issue SUPPL. 2, 2003, Pages

  Allain, Hervé ^a   Bentué Ferrer, Danièle ^a  

^a UNIVERSITÉ DE RENNES 1   (France)

Author keywords

Alzheimer's disease; Cognition; Dementia; Drugs; Inhibitors of acetylcholinesterase; Pharmacology

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; CHOLINESTERASE INHIBITOR; DIHYDROERGOTOXINE MESILATE; DONEPEZIL; GALANTAMINE; GINKGO BILOBA EXTRACT; GLUTAMATE RECEPTOR ANTAGONIST; NOOTROPIC AGENT; PIRACETAM; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; TACRINE;

ALZHEIMER DISEASE; AMNESIA; ANXIETY DISORDER; APOPTOSIS; AUTISM; COGNITION; DEMENTIA; DEPRESSION; DRUG EFFECT; DRUG MECHANISM; FRONTOTEMPORAL DEMENTIA; HUMAN; IMMUNIZATION; MULTIINFARCT DEMENTIA; NERVOUS SYSTEM DEVELOPMENT; PARKINSON DISEASE; PATHOPHYSIOLOGY; REVIEW; SYMPTOMATOLOGY;

EID: 1342343897     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-200312002-00005     Document Type: Review

References (26)

1. Bentué-Ferrer D, Michel BF, Reymann JM, Allain H. Medication in Alzheimer's disease [in French]. Rev Geriatr 2001; 26:511-522.
2. Allain H, Bentué-Ferrer D, Decombe R. Choosing a target for cognitive enhancers. Clin Ther 1990; 12:298-305.
3. Allain H, Bentué-Ferrer D, Belliard S, et al. Mild cognitive impairment: potential therapeutics [in French]. Rev Neurol (Paris) 2002; 158:S35-S40.
4. Allain H, Schück S. Drugs and cognition [in French]. La Lettre du Neurologue 2000; 4:38-43.
5. Petersen RC, Yanagihara T, Mohs RC, et al. Treatment of memory disorders, Chapter 21. In: Yanagihara T, Petersen RC, editors. Memory disorders. New York, USA: Marcel Dekker; 1991. pp. 457-503.
6. Niederhofer H, Staffen W, Mair A. Galantamine may be effective in treating autistic disorder. BMJ 2002; 325:1422.
7. Derouesné C. What is dementia? a fuzzy concept [in French]. Psychol NeuroPsychiatr Vieillissement 2003; 1:15-24.
8. Hachinski VC, Bowler JV. Vascular dementia. Neurology 1993; 43:2159-2160.
9. Etminan M, Gill S, Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. BMJ 2003; 327:7-5.
10. Allain H, Bentué-Ferrer D, Tribut O, Belliard S. Drug therapy of fronto-temporal dementia. Human Psychopharmacol 2003; 18:221-225.
11. Allain H, Bernard PM, Dartigues JF, et al. Point de vue sur la méthodologie des essais de médicaments à visée cognitive chez les sujets âgés. L'Encéphale 1994; XX:725-739.
12. Sellal F, Nieoullon A, Michel G, et al. Pharmacologie de la maladie d'Alzheimer: bilan et prospective. Rev Neurol (Paris) 2004; in press.
13. Allain H, Bentué-Ferrer D, Tribut O, et al. Alzheimer's disease: the pharmacological pathway. Fund Clin Pharmacol 2003; 17:419-428.
14. Zhou Q, Tao HW, Poo MM. Reversal and stablisation of synaptic modifications in a developing visual system. Science 2003; 300:1953-1957.
15. Allain H, Bentué-Ferrer D, Tribut O, Pinel JF. Drugs and vascular dementia. Dementia Geriatr Cogn Disord 2003; 16:1-6.
16. Friedlander RM. Apoptosis and caspases in neurodegenerative diseases. N Engl J Med 2003; 348:1365-1375.
17. Mattson MP. Ballads of a protein quartet. Nature 2003; 422:385-387.
18. Dodel RC, Hampel H, Du Y. Immunotherapy for Alzheimer's disease. Lancet Neurol 2003; 2:215-220.
19. Taubes G. Insulin insults may spur Alzheimer's disease. Science 2003; 301:40-41.
20. Deane R, Yan SD, Submamaryan RK, et al. Rage mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 2003; 9:907-913.
21. Littleton JT, Sheng M. Synapses unplugged. Nature 2003; 423:931-932.
22. Rizzoli SO, Betz WJ. All change at the synapse. Nature 2003; 423:591-592.
23. Miyazawa A, Fujiyoshi Y, Unwin N. Structure and gating mechanism of the acetylcholine receptor pore. Nature 2003; 423:949-955.
24. 2+ channels to synaptic vesicle exocytosis. Nature 2003; 423:939-948.
25. Danysz W, Parsons CG, Mobius HJ, et al. Neuroprotective and symptomatological action of memantine for Alzheimer's disease. A unified glutamatergic hypothesis on the mechanism of action. Neurotox Res 2000; 2:85-97.
26. Bentué-Ferrer D, Tribut O, Poland E, Allain H. Clinically significant drug interactions with cholinesterase inhibitors. A guide for neurologists. CNS Drugs 2003; 17:947-963.